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Key Points 
Question 
Reactivation of latent cytomegalovirus (CMV) has been detected in up to 30% of critically ill patients. 
The clinical importance of this observation is unanswered. 
Findings 
This randomised controlled trial assessed the efficacy, safety and feasibility of antiviral prophylaxis 
to prevent CMV reactivation in critically ill patients. Valganciclovir and valaciclovir both suppressed 
CMV reactivation compared to control (Kaplan-Meier: 35% vs. 8%, p=0.002), although the 
valaciclovir arm was stopped early because of higher mortality. 
Meaning 
Prophylaxis prevents CMV reactivation in critically ill patients; further research would be needed to 
determine clinical efficacy and safety. 
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Abstract 
Importance:  
Latent Cytomegalovirus (CMV) infection is present in over half of the adult population and viral 
reactivation, where virus becomes measurable in body fluids such as blood, can occur in up to a third 
of these individuals during episodes of critical illness. 
Objective: 
To determine whether antiviral therapy is safe and effective for preventing CMV reactivation in a 
general population of critically ill patients. 
Design: 
Single centre, open-label, randomised, controlled trial recruiting between January 2012 and January 
2014. 
Setting: 
Large 100 bedded intensive care unit in England, UK 
Participants: 
124 CMV-seropositive patients undergoing mechanical ventilation for at least 24 hours in intensive 
care. Baseline characteristics were similar between groups with mean age 57 years and mean 
APACHE II score 17.6.  
Interventions: 
Patients were randomised to receive anti-CMV prophylaxis with valaciclovir (N=34) or low dose 
valganciclovir (N=46) for up to 28 days to suppress CMV reactivation, or to a control group with no 
intervention (N=44).  
Main Outcome Measure: 
Time to first CMV reactivation in blood within the 28 day follow up period following initiation of 
study drug. 
Results:  
Viral reactivation in blood occurred in 12 patients randomised to the control group, compared with 
one reactivation in the valganciclovir group and two reactivations in the valaciclovir group (HR=0.1, 
95% CI: 0.04-0.5 for combined treatment groups vs. control). Although this trial was not powered to 
assess clinical endpoints, the valaciclovir arm was halted prematurely because of higher mortality; 
14 of 34 patients (41%) had died by 28 days, compared with 5 of 37 (13.5%) patients in the control 
arm at the point of the decision to halt this arm. Other safety endpoints showed similar outcomes 
between groups. 
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Conclusion and Relevance:  
Antiviral prophylaxis with valaciclovir or low dose valganciclovir suppresses CMV reactivation in the 
setting of critical illness. However, given the higher mortality, a large-scale trial would be needed to 
determine the clinical efficacy and safety of CMV suppression. 
Trial Registration: 
Clinicaltrials.gov, NCT01503918, https://clinicaltrials.gov/ct2/show/NCT01503918 
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Introduction 
Herpesvirus infections are widely prevalent within the human population and establish a state of 
chronic infection. Primary infection with Cytomegalovirus (CMV) is usually clinically silent and most 
individuals become chronically infected during their lifetime.1-3 The presence of measurable CMV 
virus in body fluids such as blood is prevented by a competent host immune system acting to 
suppress the virus.  If this response is inadequate, reactivation occurs (i.e. CMV is present in body 
fluids).  CMV is thus often detectable in immunosuppressed patients. Viral reactivation is associated 
with a wide range of clinical problems and antiviral prophylaxis has become well established as 
therapy in high risk settings, such as transplantation and therapeutic immunosuppression.4-8  
Critical illness impairs host defence mechanisms, particularly in those patients with a systemic 
inflammatory response, and this increases the risk of CMV reactivation which has been reported as 
affecting up to 30% of critically ill patients. 9-22 
Clinical risk factors associated with reactivation of CMV include the duration of intensive care unit 
(ICU) stay, pneumonia, sepsis, and high disease severity.18,23 There are also many biological factors 
that act to increase the frequency of CMV reactivation in critical illness, including direct stimulation 
of viral replication resulting from endotoxin and inflammatory cytokine release and the increased 
levels of catecholamines.24-29 In addition to direct tissue damage, CMV viremia may itself serve to 
suppress normal immune function and increase the risk of secondary infective complications.30,31 
Indeed, systematic reviews have demonstrated that mortality in patients with CMV reactivation was 
on average doubled compared to those without viremia.23,32 Limaye et al. have further 
demonstrated a direct correlation between CMV viral load and mortality.9 
A number of antiviral agents are available with activity against CMV. Both valganciclovir and 
valaciclovir (orally active forms of ganciclovir and aciclovir) are used for prophylaxis against CMV 
reactivation in organ transplant recipients.  However, despite the potential for benefit, there are 
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currently no data evaluating their efficacy as prophylaxis for viral reactivation in non-
immunosuppressed patients in the intensive care unit.25,33  
We have performed a proof of principle study, designed to assess the efficacy, safety and feasibility 
of antiviral prophylaxis for suppressing CMV reactivation in critically ill patients receiving support in 
the ICU. Two active treatment arms were chosen, one using low dose valganciclovir and the other 
using valaciclovir. Both regimens have been used widely outside critical care settings. Valganciclovir 
has been shown to have a less favourable side effect profile but demonstrates increased activity 
against CMV. In contrast, valaciclovir requires high dosage administration because of its relatively 
limited activity against CMV but is generally well tolerated. Here we report the results of this study. 
Methods 
Study Design 
We conducted a single centre, proof of principle, open-label, randomised, controlled, three armed 
study of two anti-CMV prophylaxis treatments and standard care (no antiviral prophylaxis; control 
group) in CMV-seropositive patients in the ICU at Queen Elizabeth Hospital Birmingham, UK between 
January 2012 and January 2014. The study was approved by the National Research Ethics Service 
Committee, London. The trial was registered with clinicaltrials.gov, study identifier NCT01503918.  
We adopted a two-stage contingent consent process: first for a screening sample to determine CMV 
positivity, and second for recruitment to the interventional trial in the event of positive screening. 
Generally, sedated patients did not have capacity to give informed consent, and so consent was 
sought from a personal or professional legal representative prior to randomisation. Patient consent 
to continue as a trial participant was sought once capacity had been regained.   
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Participants 
Patients were eligible for the study if CMV seropositive, already in the ICU for more than 24 hours 
and mechanically ventilated, with this anticipated to continue for at least 48 hours. 
As the study was designed to examine patients without pre-existing immune suppression, the 
following exclusions were applied: known or suspected congenital or acquired immunodeficiency; 
receipt of immunosuppressive medication within 30 days; and chemotherapeutic agents within 6 
months. Corticosteroids were not an exclusion criterion if the dose was less than 10mg/day 
prednisolone (or equivalent), short courses of up to 1mg/kg prednisolone (or equivalent) for 
exacerbations of COPD for up to 14 days, or ‘stress dose’ hydrocortisone up to 400mg/day as part of 
intensive care support. Patients were also excluded from randomisation if they tested as CMV IgG 
seronegative, were under 18 years, if onset of acute illness was more than 7 days at the point of 
randomisation, they were in receipt of systemic antiviral medication within 7 days (use of oseltamivir 
allowed), expected survival less than 48 hours, neutropenia <1·0 x109/L, they had suffered an 
isolated brain injury, known allergy to any study drugs, or if known to be pregnant or breast feeding. 
Intervention and randomisation 
Eligible participants were randomised in a 1:1:1 ratio to receive valganciclovir, valaciclovir or control 
by telephone access to a computer-generated random treatment allocation sequence (Birmingham 
Clinical Trials Unit (BCTU), UK). The randomisation was stratified by age (age ≤50 years or >50 years). 
Although patients and treating physicians were not masked to the assigned treatment group, CMV 
quantitative PCR (QPCR) results were not available during the study period and were block 
processed at a later date; laboratory staff were blinded to treatment allocation. Interim safety 
analyses were performed at 6 months, and at intervals thereafter by the independent Data 
Monitoring Committee (DMC).   
Participants randomised to one of the two study drug arms received either valganciclovir or 
valaciclovir prophylaxis.  Low dose valganciclovir prophylaxis has been established as the mainstay of 
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prophylaxis in other groups.  High dose valaciclovir has the benefit of activity against a wider group 
of viruses, as well as a low toxicity profile.  Both low dose valganciclovir and high dose valaciclovir 
have been used successfully in trials of immunosuppressed patients, and subsequently in the clinical 
setting. Patients randomised to valganciclovir received 450mg valganciclovir, once a day by the 
enteral route. Patients in this group unable to receive enteral medication received intravenous 
ganciclovir 2·5mg/kg ideal bodyweight, once a day until enteral absorption was established. Patients 
randomised to receive valaciclovir received 2g valaciclovir, four times a day by enteral route. 
Patients unable to receive enteral medication received intravenous aciclovir 10mg/kg ideal 
bodyweight, three times a day until enteral absorption was established. 
In both arms, the study drug was initiated on the day of randomisation and continued for a period of 
28 days in the ICU. The drug was discontinued after a minimum of 14 days if patients were 
discharged from the ICU to the ward. The drug was discontinued if patients were discharged from 
hospital. Treatment dosing was modified in the presence of renal impairment (eTable S1). Study 
drug was withdrawn in the presence of severe neutropenia (<1·0 x109/L), requirement for G-CSF 
therapy, or at the request of the clinical team overseeing patient care.  
The patient group randomised to receive no antiviral prophylaxis received standard care. Antiviral 
medication could be initiated if the clinical team overseeing the care of the patient deemed it 
necessary for therapeutic reasons. 
Data Collection  
We obtained patients’ acute physiology and chronic health evaluation (APACHE II) scores from our 
local case mix programme database of the Intensive Care National Audit and Research Centre 
(ICNARC). Physiological and routine blood test results, including data allowing calculation of daily 
sequential organ failure assessment (SOFA) score34,35, was collected for 28 days or until death or 
discharge from hospital if this was sooner. Patients were followed up until death or hospital 
discharge. 
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Specimens of plasma, urine, throat swab and non-directed bronchiolar lavage (NDBL) fluid were 
collected on day one, and at 5 (± 1) day intervals during the 28 day study period (on days 1, 6, 11, 16, 
21 and 26), or until patient death or discharge from hospital, if this was sooner.  Anonymised 
specimens were sent to the Microbiology Department, University Hospitals Birmingham, to be 
analysed for the presence of CMV DNA using a QPCR assay (Abbott™ Diagnostics, Maidenhead, UK. 
limit of detection 20 copies/ml). NDBL samples were performed on patients with no 
contraindication, whose trachea remained intubated at the required sampling time point. Blood 
specimens underwent analysis for tumour necrosis factor (TNF) and interleukin-6 (IL-6) levels using 
Proseek® Multiplex, Olink Bioscience, Uppsala, Sweden. Protein concentrations were evaluated 
using assay specific units; NPX units (Normalised Protein eXpression), on Log2 scale, normalised to 
minimise intra- and inter-assay variation, in which a high value corresponds to a high protein 
concentration. 
Outcomes 
The primary outcome measure was time to first reactivation of CMV in blood (defined as above the 
lower limit of the QPCR assay which was 20 copies/ml) from initiation of study drug until day 28, 
excluding those patients who had already reactivated on the day of enrolment. Secondary outcomes 
were time to first reactivation of CMV by day 28 in urine, throat swab and NDBL specimens. Time to 
>1,000 and >10,000 copies/ml, peak CMV viral load and area under the curve (AUC) were also 
planned analyses. Secondary clinical outcome measures included mortality by 28 days after 
randomisation; organ failure free days (SOFA score <2) and moderate organ dysfunction free days 
(SOFA score <5) at 28 days36,37; time to discharge from ICU and time to discharge from hospital. 
Assessments of drug safety were time to neutropenia (<1·0 x10-9/L), time to thrombocytopenia 
(platelet count <50 x 10-9/L), requirement for ‘rescue’ G-CSF therapy or premature cessation of study 
drug, number of platelet transfusions, and development of renal insufficiency (defined as both: 
creatinine clearance of <60ml/min; and creatinine clearance of <30ml/min or requirement for renal 
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replacement therapy). Cytokine analysis was performed on blood, with change in TNF-α and IL-6 
from time of randomisation to day 14 and 28 selected a priori as exploratory outcome measures.  
Statistical Analysis 
The sample size was based on studies of CMV reactivation rates in CMV seropositive patients within 
the ICU, where reactivation rates of up to 30% have been observed, and high drug efficacy seen in 
other patient populations. The target sample of 141 patients (47 patients in each group) was 
determined using 90% power at p=0·05 to detect a difference in CMV reactivation from 30% in the 
control group to 5% in the treatment group in CMV seropositive critically ill patients.  
Primary analyses compared the combined treatment groups with the control group. As the 
valaciclovir arm was closed early due to safety concerns, it was decided by the trial team and BCTU 
statisticians (who were blind to the data at this time) to also compare valganciclovir with the control 
group. Time to event analyses were performed using survival analysis methods to compare time to 
first CMV reactivation between groups. Kaplan-Meier plots were produced and unadjusted Cox 
proportional hazard models used to report hazard ratios (HR) and 95% confidence intervals (95% CI). 
All analyses were performed on an intention to treat principle, whereby patients included in the 
analysis were analysed according to the treatment group to which they were randomised regardless 
of whether they received this treatment. As the primary outcome of the study was to measure the 
efficacy of antiviral drugs to prevent CMV reactivation, patients were excluded from the analyses of 
CMV viral load if viral reactivation had already taken place before initiation of study drug on the day 
of recruitment. In the event of patient discharge from hospital or death, the results were censored 
at the most proximate blood CMV QPCR sample point. Analysis of clinical and safety outcomes 
included all patients and so included those who had reactivated CMV in any body fluid at baseline. 
All analyses were undertaken using SAS version 9.2 (Cary, NY, USA). 
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Role of the Funding Source 
This paper presents independent research funded by the National Institute for Health Research 
(NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number 
PB-PG-1010-23225). The views expressed are those of the authors and not necessarily those of the 
NHS, the NIHR or the Department of Health. 
Results 
 
Patients 
Between January 2012 and February 2014, 124 patients were randomised into the trial; 44 in the 
control group, 34 in the valaciclovir group (recruitment stopped prematurely to this arm, see next 
section) and 46 in the valganciclovir group (Figure 1). Baseline characteristics were similar across the 
three groups (eTable S2). Disease severity scoring at ICU admission was similar between groups, with 
mean APACHE II score of 17.5 in the control group, 17.9 in the valaciclovir group and 17.4 in the 
valganciclovir group. Main category of diagnosis at enrolment is shown in eTable S2. 
Cessation of Valaciclovir Arm 
Recruitment into the valaciclovir arm was ceased in September 2013, following an interim analysis 
presented to the independent DMC, who advised that this arm be closed because of significantly 
higher mortality in this group. At this point, 34 participants had been recruited into the valaciclovir 
arm, 14 (41%; 95% CI: 25%-58%) of whom had died by 28 days, compared with 5 of 37 (13.5%; 95% 
CI: 2%-25%) participants in the control arm, and 7 of 34 (20.6%; 95% CI: 7%-34%) participants in the 
valganciclovir arm. To investigate potential associations between study drug use and cause of death, 
an independent case record review was performed. Reviewers were intensive care doctors 
independent of the study team; each set of case notes was examined by two reviewers blinded to 
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group allocation.  The reviewers identified all deaths as expected and attributable to the underlying 
disease. By the end of the study, the control group mortality increased from 13.5% to 15.9% for 28 
day mortality, and to 20.5% for hospital mortality.  
Study drug adherence 
Nine participants had the study drug stopped prematurely during the 28 day trial period (4 in 
valaciclovir group and 5 in valganciclovir group). Two patients in the valaciclovir group had the study 
drug stopped after 5 and 7 days by the supervising clinician because of a change to palliative care. 
One patient in the valganciclovir group had the study drug stopped after 6 days at the request of 
their personal legal representative (with permission to continue sampling and data collection 
following withdrawal of study drug). The other six patients had the study drug stopped prematurely 
because of possible adverse events (n=2) or serious adverse events (SAE; n=4). In the valaciclovir 
group, two patients had the study drug stopped due to rashes, whilst four patients stopped drug 
early in the valganciclovir group, one due to allergic reaction, one due to a rash and two due to 
clinical concerns related to low platelet counts. No patients had study drug stopped because of the 
predefined stopping points of neutropenia or use of G-CSF.  
Primary Outcome 
Figure 2 shows CMV blood viral load over time, and includes all enrolled patients split into two 
groups; those receiving antiviral prophylaxis of any form, and those in the control arm receiving no 
antivirals.  14 patients had CMV viremia on the day of enrolment (shown in red in figure 2) and were 
therefore excluded from the primary analysis of drug efficacy (time to reactivation). Viral 
reactivation in blood occurred in 12 patients randomised to the control group compared with 3 
reactivations in the combined active treatment group (Kaplan-Meier: 35% vs. 8%, HR=0.1, 95% CI: 
0.04-0.5, p=0.002 for combined treatment group vs. control) (Table 1, Figure 3a). There was one 
reactivation in the low dose valganciclovir group (HR=0.08, 95% CI: 0.01-0.6, p=0.01 for 
valganciclovir vs. control; Figure 3b).  
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Secondary Outcomes 
CMV reactivation in blood, urine, NDBL, and throat swab are presented in Table 1. Blood was the 
most sensitive body fluid for the demonstration of CMV reactivation in this study, although this may 
reflect the more complete dataset, with 83% patients (15 out of 18) who reactivated in any body 
fluid, at least doing so in blood. NDBL data were available beyond baseline in only 28% of patients 
due to difficulties in obtaining subsequent samples (compared to ≥85% for blood, urine and throat), 
meaning this data should be interpreted with caution.  
Clinical endpoints are shown in Table 2. In total, 9 of 44 patients died in hospital in the control group 
compared to 15 of 34 patients in the valaciclovir group and 12 of 46 patients in the valganciclovir 
group. The relative risk for hospital mortality was 1.3 (95% CI: 0·6-2·7) in the valganciclovir group 
compared to control, and 2.2 (95% CI: 1·1-4·3) for the valaciclovir group compared to control. Seven 
(16%) patients reported SAEs in the control group, compared to 10 (29%) in the valaciclovir group 
and 16 (35%) in the valganciclovir group. The relative risk for a patient experiencing an SAE was 1.8 
(95% CI: 0.8-4.4) when comparing the valaciclovir with control group, 2.2 (95% CI; 1.0-4.8) when 
comparing the valganciclovir with control group, and 2.0 (95% CI: 1.0-4.3) when comparing the 
combined treatment groups with the control group. The time to renal impairment (Creatinine 
clearance <60 ml/min) and severe renal impairment (creatinine clearance <30 ml/min or 
requirement for renal replacement therapy) was similar between the combined treatment groups 
and control: HR: 1.2 (95% C.I: 0.7-2.0), and HR: 1.0 (95% C.I: 0.6-1.8) respectively. Comparing 
valaciclovir with control gave similar results: HR: 1.5 (95% C.I: 0.9-2.8) and HR: 1.2 (95% C.I: 0.6-2.4) 
for renal impairment and severe renal impairment respectively. There was no evidence of any 
difference in levels of bone marrow suppression between groups; there were no reports of 
neutropenia, and the risk of thrombocytopenia was similar between combined treatment groups 
and control (HR: 1.0 (95% C.I: 0.5 to 2.2). 
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Exploratory Outcomes 
A pre-planned exploratory analysis assessing changes in TNF-α and IL-6 from time of randomisation 
to day 14 and day 28 was undertaken. To accommodate variations in sampling times, we used time 
windows rather than a fixed time point: if samples for the pre-specified days were not available, 
samples from days 13 and 15 were included in the day 14 analysis, and samples from days 21 to 28 
were included in the day 28 analysis. These data were only available for patients who were in 
hospital at the time the sample was taken and as such the analysis is based on a limited group of 
patients. Results from patients allocated to valganciclovir were compared with control. The mean 
difference in change in TNF between day 0 and day 13-15 was -0.01 (95% C.I: -0.16-0.14) and 
between day 0 and day 21-28 was -0.05 (95% C.I: -0.13-0.02) (Table 2).  The mean difference in 
change in IL-6 between day 0 and day 13-15 was -0.25 (95% C.I: -1.48-0.98) and between day 0 and 
day 21-28 was -0.11 (95% C.I: -1.41-1.20). 
Planned Analyses Not Presented 
Time to >1,000 and >10,000 copies/ml and AUC were also planned analyses for the blood, urine, 
NBDL and throat sample data. There were very few samples with >1,000 copies/ml (3 in total): (1 in 
blood, 2 in NDBL) or >10,000 copies/ml (none), and incomplete sample profiles caused by death or 
discharge from hospital or non-availability of sampling access (patients whose tracheas were 
extubated preventing NDBL) limited the utility of AUC analyses.  
Discussion 
The results of this study, designed to assess the efficacy, safety and feasibility of antiviral prophylaxis 
in CMV seropositive non-immunosuppressed critically ill patients, demonstrate that CMV reactivates 
in around a third of critically ill patients, and that reactivation can be suppressed from 35% to 3%, 
through the use of antiviral prophylaxis with low-dose valganciclovir. Blood was the most sensitive 
body fluid for the detection of CMV reactivation in this study, with 83% of patients who reactivated 
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doing so in at least blood.  This may reflect the more complete dataset for this body fluid, as it was 
not possible to collect other specimens as consistently because of patient constraints including 
anuria (urine), or tracheal extubation (NDBL).  Viral loads for patients with CMV viraemia were 
generally low (range 25 – 1382 copies/ml). 
Although valaciclovir was effective at suppressing CMV, it was difficult to administer (high frequency 
of administration of both routes, inability to crush and administer valaciclovir enterally via 
nasogastric tube, and potential risk of thrombophlebitis from intravenous administration). 
Valaciclovir was associated with increased mortality, although it is unclear why.  All study deaths 
were classed as expected and attributable to the underlying disease by independent blinded 
reviewers. The incidence of renal impairment and bone marrow suppression, both potential side 
effects of the treatment drugs, were similar between groups, although this study was not powered 
to identify differences. It is possible that critically ill patients, commonly developing significant organ 
dysfunction, are more susceptible to the potential side effects of  antiviral drugs, although these 
drugs have long been used safely for CMV reactivation suppression in the transplant population. 
Herpesviruses have the capacity to modify host immune defences including TNF-regulated signalling 
pathways.38 Elevated levels of TNF and IL6 may mediate the higher mortality rates associated with 
CMV antibody response in an elderly Latino population39  Survivors of critical illness with CMV 
reactivation are reported to have a more marked pro-inflammatory biomarker profile (including 
elevated IL6 levels) than seronegative survivors three months after ICU discharge.40 However, in our 
exploratory analysis, we find no consistent pattern in trends for IL6 or TNF between the study groups 
(Table 2).  We suspect that if CMV-related cytokine changes occur, they are likely to be masked by 
the pro-and anti-inflammatory components of acute critical illness.   
There are a number of limitations to our study. Although this was a single centre study, and the 
representativeness of patients and generalizability of the results would have been improved by 
recruiting from multiple sites, this study was conducted in the largest ICU in Europe, with 100 beds, 
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including both general and specialty Intensive care beds. For practical reasons, the study was 
necessarily open-label. The primary outcome measure of time to CMV reactivation in blood was felt 
to be robust, since laboratory staff were blinded to treatment allocation. The lack of blinding could 
however have influenced other data, such as the recording of adverse events.  Although a third of 
patients in the control arm demonstrated CMV viremia, the viral loads were generally low when 
compared to those found in immunosuppressed patients, and this may be relevant when assessing 
the importance of viral suppression with drugs. The valaciclovir arm was terminated early because of 
safety concerns and this led to a smaller sample size than planned in this group. Valaciclovir has 
been used for many years and examined in other studies outside of the critical care setting with few 
side effects, with the additional benefit over valganciclovir of activity against other herpesviruses.41-
43 However, the challenges of administering the drug to critically ill patients make it an unsuitable 
option for any subsequent trial powered to assess clinical outcomes. It could be questioned whether 
prophylactic therapy, as chosen in this study, is preferable to early treatment of active reactivation. 
Prophylaxis is conceptually more attractive, as it prevents viral reactivation before direct systemic 
and tissue injury takes place, and is simpler when many ICUs do not have access to rapid CMV 
assay.44,45 Prophylaxis has been chosen as the standard in many other populations, with more 
effective CMV suppression, although at the expense of a higher incidence of side effects.6 However, 
treatment following reactivation minimises population drug exposure, which may be particularly 
important in the setting of polypharmacy associated with critical illness. 
In conclusion, this study demonstrates that antiviral prophylaxis effectively suppresses CMV 
reactivation in critically ill patients, and is best achieved through the use of low dose valganciclovir, 
administered enterally, or intravenously as ganciclovir.  Valaciclovir was associated with an increased 
mortality, although it was not possible to identify a causal link between the drug administration and 
death. The safety and efficacy of antiviral prophylaxis to prevent  CMV reactivation in this setting can 
only be determined by conducting a large-scale trial with close monitoring of clinical and patient-
centred outcomes. 
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Figures/Tables 
 
Table 1: Reactivation and peak viral load data for CMV viral load by PCR 
(copies/ml) for each body fluid.   
 Control 
 
Valaciclovir Valganciclovir HR (95% CI) 
(combined 
vs. control) 
HR (95% CI) 
(valganciclovir 
vs. control) 
Blood N=44 N=34 N=46   
Number of Reactivations 12 2 1 0·1 
(0·04 to 0·5) 
p=0·002 
0·08 
(0·01 to 0·6) 
p=0·01 
Median viral load for first positive 
PCR (range) 
33.0  
(22 – 95) 
29.5  
(27 – 32) 
37 
(-) 
  
Median peak viral load in patients 
who reactivated (range) 
37·5 
(25 – 1382) 
29·5 
(27 – 32) 
60 
(-) 
- - 
      
Urine      
Number of Reactivations 4 0 0 - - 
Median peak viral load in patients 
who reactivated (range) 
48·5 
(28 – 278) 
- - - - 
      
NDBL      
Number of Reactivations 2 0 2 0·2 
(0·02 to 2·6) 
p=0·2 
0·3 
(0·03 to 3·5) 
p=0·3 
Median peak viral load in patients 
who reactivated (range) 
843 
(22 – 1664) 
- 423·5 
(25 – 822) 
- - 
      
Throat
* 
     
Number of Reactivations 4 2 1 0·5 
(0·1 to 2·3) 
p=0·4 
0·3 
(0·03 to 2·4) 
p=0·2 
      
Any Body Fluid **      
Number of Reactivations 14 2 2 0·1  
(0·03 to 0·5) 
0·2  
(0·05 to 0·5) 
HR=Hazard Ratio; 95% CI=95% Confidence Interval; NDBL=non-directed bronchiolar lavage 
Patients who reactivated at baseline (on day 1) are excluded from this analysis (n=14 for blood, n=2 for urine, n=6 for NDBL, n=6 for throat swab), 
patients with only data at baseline are censored at day 1 (n=12 for blood, n=11 for urine, n=47 for NDBL, n=11 for throat swab), and patients are 
censored at discharge from hospital or death if this occurred before the end of scheduled sampling.  Patients with no samples (blood n=0, urine 
n=7, NDBL n=38, throat swab n=0) are censored at day 1. 
* Throat swabs are either positive or negative, so viral loads are not presented. 
** Reactivation in blood, urine, NDBL, or throat swab at any point excluding baseline. 
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Table 2: Clinical, safety & exploratory cytokine outcomes.   
  Control 
(N=44) 
Valaciclovir 
(N=34) 
Valganciclovir 
(N=46) 
Secondary Clinical Outcome Measures    
  Organ failure free days  
  (SOFA score<2) 
Median 3·5 1·5 2·0 
IQR (0 - 18) (0 - 13) (0 - 11) 
Range (0 – 31) (0 – 24) (0 – 36) 
  Moderate organ failure free days  
  (SOFA score<5) 
Median 18·0 11·0 16·5 
IQR (2 - 24) (0 - 22) (4 - 21) 
Range (0 – 41) (0 – 28) (0 – 44) 
  Discharged from ICU by 3 months† N (%) 36 (82) 21 (62) 34 (74) 
  Discharged from Hospital by 3 
months† 
N (%) 30 (68) 17 (50) 28 (61) 
  ICU Duration of Stay (days) Median 11.5 12.0 16.0 
 IQR (7 – 16) (7 – 31) (11 – 27) 
  Number of SAEs forms returned N 7 12 18 
  Number of Patients reporting SAEs N (%) 7 (16) 10 (29) 16 (35) 
  Mortality (28 day) N (%) 7 (16) 14 (41) 10 (22) 
  Mortality (Hospital) N (%) 9 (20) 15 (44) 12 (26) 
     
Safety Outcomes     
  Requirement for G-CSF therapy N (%) 0 (0) 0 (0) 0 (0) 
  Neutropenia (<1 x10
-9
/L) N (%) 0 (0) 0 (0) 0 (0) 
  Platelet count < 50 x10
-9
/L) N (%) 10 (23) 9 (26) 10 (22) 
  Platelet transfusions N 44 32 42 
 Median 0 0 0.2 
 IQR (0 - 0) (0 - 0.5) (0 - 1) 
  Renal Insufficiency     
      CrCl<60ml/min N (%) 23 (52) 22 (64) 24 (52) 
      CrCl<30ml/min or required dialysis N (%) 19 (43) 16 (47) 18 (39) 
     
Exploratory Cytokine Analyses 
TNF (NPX units) Control  Valganciclovir 
Mean change (SD) between day 0 and day 14 N = 23 
0·07 (0·18) 
 N = 26 
0·05 (0·33) 
Mean difference (95% CI) -0·01 (-0·16 to 0·14) 
Mean change (SD) between day 0 and day 28  N = 23 
0·04 (0·15) 
 N = 22 
-0·01 (0·10) 
Mean difference (95% CI) -0·05 (-0·13 to 0·02) 
   
IL-6 (NPX units) Control  Valganciclovir 
Mean change (SD) between day 0 and day 14  N = 23 
-1·09 (2·46) 
 N = 26 
-1·34 (1·82) 
Mean difference (95% CI) -0·25 (-1·48 to 0·98) 
Mean change (SD) between day 0 and day 28  N = 23 
-1·91 (2·14) 
 N = 22 
-2·01 (2·18) 
Mean difference (95% CI) -0·11 (-1·41 to 1·20) 
 
SOFA=Sequential organ failure assessment; CrCl=Creatinine clearance; G-CSF=Granulocyte-colony stimulating factor; SAEs=Serious 
adverse events. IQR=Interquartile range. SD=Standard deviation; TNF=tumour necrosis factor; IL-6=interleukin-6. NPX – normalised 
protein expression. For day 14, samples taken between days 13-15 were used. For day 28, samples taken between days 21-28 were 
used. †Based on patients who remained alive and could be discharged from hospital.  By three months, all patients (except one) who 
could have been discharged (i.e. alive patients) had been discharged from hospital. 
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Figure footnotes: 
 
Figure1: Trial flowchart 
 
Figure 2: CMV viral load in blood in combined treatment groups (valaciclovir and valganciclovir arms) versus 
control group over the 28 day period of data collection.  Each line represents a single patient. Lines shown in 
red represent patients who had CMV viremia on day of enrolment, and thus were excluded from primary 
analysis of time to CMV reactivation.  All enrolled patients are shown here to show differences in viral load 
over time with or without antiviral prophylaxis. 
 
Figure 3a: Time to CMV viral reactivation in blood in combined treatment groups (valaciclovir and 
valganciclovir arms) versus control group. 
Figure 3b: Time to CMV viral reactivation in blood in valganciclovir group versus control group 
 
